4.7 Article

Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia

Journal

LEUKEMIA
Volume 30, Issue 8, Pages 1672-1681

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2016.69

Keywords

-

Funding

  1. Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award
  2. NMRC Centre Grant
  3. National Research Foundation Singapore
  4. Singapore Ministry of Education under its Research Centers of Excellence initiative
  5. NIH/NCI [R01CA026038-35]
  6. NCI [CA31946]
  7. Deutsche Forschungsgemeinschaft [HE 5240/5-1]
  8. Senior Fellowship program of Wellcome DBT India Alliance, New Delhi, India [IA/S/11/2500267]
  9. Council for Scientific and Industrial Research (CSIR), New Delhi, India
  10. Samuel Oschin Comprehensive Cancer Institute (SOCCI) at Cedars-Sinai Medical Center through the Eleanor and Glenn Padnick Discovery Fund in Cellular Therapy Project
  11. NCIS Centre Grant Seed Funding
  12. [OMRPG3C0021]
  13. [MOHW104-TDU-B-212-124-006]

Ask authors/readers for more resources

Acute promyelocytic leukemia (APL) is a subtype of myeloid leukemia characterized by differentiation block at the promyelocyte stage. Besides the presence of chromosomal rearrangement t(15; 17), leading to the formation of PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) fusion, other genetic alterations have also been implicated in APL. Here, we performed comprehensive mutational analysis of primary and relapse APL to identify somatic alterations, which cooperate with PML-RARA in the pathogenesis of APL. We explored the mutational landscape using whole-exome (n = 12) and subsequent targeted sequencing of 398 genes in 153 primary and 69 relapse APL. Both primary and relapse APL harbored an average of eight non-silent somatic mutations per exome. We observed recurrent alterations of FLT3, WT1, NRAS and KRAS in the newly diagnosed APL, whereas mutations in other genes commonly mutated in myeloid leukemia were rarely detected. The molecular signature of APL relapse was characterized by emergence of frequent mutations in PML and RARA genes. Our sequencing data also demonstrates incidence of loss-of-function mutations in previously unidentified genes, ARID1B and ARID1A, both of which encode for key components of the SWI/SNF complex. We show that knockdown of ARID1B in APL cell line, NB4, results in large-scale activation of gene expression and reduced in vitro differentiation potential.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available